Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company

HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility

Fineline Cube Sep 29, 2024

HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...

Company Deals

Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation

Fineline Cube Sep 29, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...

Company Drug

Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company

3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline

Fineline Cube Sep 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...

Policy / Regulatory

China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions

Fineline Cube Sep 29, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Policy / Regulatory

China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel

Fineline Cube Sep 29, 2024

The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...

Company Deals

OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor

Fineline Cube Sep 28, 2024

Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...

Company Drug

Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...

Company Drug

AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC

Fineline Cube Sep 27, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Deals

Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...

Company Deals

Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation

Fineline Cube Sep 27, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...

Company Deals

FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism

Fineline Cube Sep 27, 2024

The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...

Policy / Regulatory

Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024

Fineline Cube Sep 27, 2024

The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...

Company Deals

Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA

Fineline Cube Sep 27, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company

China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals

Fineline Cube Sep 27, 2024

The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...

Policy / Regulatory

Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs

Fineline Cube Sep 27, 2024

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...

Company Deals

Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China

Fineline Cube Sep 27, 2024

Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...

Drug

FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers

Fineline Cube Sep 27, 2024

The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) convened on September 26 to scrutinize the...

Company Drug

2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma

Fineline Cube Sep 26, 2024

2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...

Posts pagination

1 … 254 255 256 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.